In 2020, COVID-19 redefined global health infrastructure, travel norms and daily habits. Today, even though most of the world is back to business as usual, SARS-CoV-2, the virus that triggered a global pandemic still remains silently persistent. With new data emerging in 2025, it's obvious that even if the severity of the virus had reduced for most, its mutation keeps impacting populations in new and complex ways.

Also Read: President Trump Says Media Reports On His Health Are All 'Fake, Seditious, Treasonous'

So, what is COVID in 2025 like? From nuanced changes in patterns of symptoms to news on vaccine immunity and AI-driven virus forecasting, here's a closer look at the latest direction of COVID and its continued influence.

While hospitalizations and COVID-19 deaths have significantly slowed from pandemic highs, the virus is hardly gone. In Australia alone, there were 58,000 cases of COVID so far in 2025, though experts say the real numbers are much greater, given decreasing testing and underreporting.

Sentinel surveillance statistics by FluCan, a network of 14 hospitals, reported 781 hospitalizations due to COVID complication in the first quarter of 2025 alone. Another 289 deaths due to respiratory infections caused by COVID happened in the first two months of the year. These statistics point out that, although COVID seems less formidable now, it is still a critical healthcare issue for some sections of the population.

Also Read: Inside The 'Flu-Nami' Surge: Why 2025 Is the Worst Flu Year For UK

Who Is Still at Risk of Severe COVID?

Currently, the vast majority of individuals who develop COVID have a mild, self-limiting illness. Nonetheless, the following groups are still at risk:

• Older adults, especially those over the age of 70
• Immunocompromised persons, including cancer patients
• Individuals with chronic disease, including diabetes and cardiovascular disease
• Socially disadvantaged populations, including those experiencing homelessness

Social disparities persist to influence health outcomes. In the UK, residents of the most deprived neighborhoods are twice as likely to be admitted to hospital with infectious diseases as those in better-off neighborhoods.

Unique Symptoms of New COVID

The typical COVID symptoms are fever, cough, sore throat, and shortness of breath — remain among the most frequently reported. Yet, newer strains have brought back some distinct symptom trends:

Also Read: Measles Outbreak: Over 250 Exposed in South Carolina; How Did This Once Eliminated Disease Come Back?

Early in the pandemic, anosmia, or the acute loss of taste or smell, was one of COVID's defining symptoms. The symptom was less frequent with Omicron, but a recent report from a French study indicates a return of anosmia in infections involving the JN.1 variant.

Anosmia is now more variant-specific, so it is a key symptom to monitor for new variants.

One of the key distinguishing factors between COVID and other respiratory diseases such as pneumonia or the flu is the lingering of symptoms, a condition now commonly known as Long COVID.

Scientists at the University of Texas matched patient data between COVID, influenza, and pneumonia. The analysis concluded that symptoms of COVID lasted longer and differed in intensity and nature. Brain fog, breathlessness, and fatigue were the most likely of the symptoms to linger months post-infection. Of interest, these post-viral symptoms appeared more frequently among the unvaccinated.

How Long Does COVID Last in 2025?

For the majority of healthy patients with mild to moderate illness, COVID symptoms disappear in 7 to 10 days. Individuals can, however, be infectious from 48 hours prior to symptom onset until around 10 days after infection.

Notably, symptom duration and recovery vary depending on various factors:

Infection severity: Severe infections may have weeks- or months-long symptoms

Vaccination status: Those who are vaccinated tend to recover more quickly and experience fewer ongoing symptoms

Past history of infection: Future infections are shorter and less symptomatic

A UK study of 5,000 healthcare workers found that fatigue fell progressively with each reinfection — 17.3% after the first, 12.8% after the second, and only 10.8% after the third.

Why Testing Still Matters Even in 2025?

COVID testing continues to be an important tool, particularly in symptomatic people, those with recent contact, or who are high-risk groups. Rapid antigen tests (RATs) are easily accessible, yet a negative RAT is not necessarily conclusive of non-infection — especially in the early phase.

Confirmatory PCR testing is still the gold standard for reliable detection and is advised in individuals who are looking for early medical intervention, particularly in the immunocompromised.

While isolation is no longer required in most areas, public health recommendations include staying home when sick and wearing a well-fitting mask when out in public.

Is Vaccination Still The Most Effective Shield?

COVID vaccines remain effective against severe illness and symptomatic infection. Recent European data (awaiting peer review) indicate that vaccines were 66% effective at preventing symptomatic COVID this winter.

2025 vaccination recommendations are:

• Adults 65–74: Boosters every 12 months

• Adults 75 and older: Boosters every 6 months

• High-risk adults (18+): Eligible for a booster every 6 months

• A wide-ranging overview of more than 4,300 studies determined that fully vaccinated individuals were 27% less likely to develop long COVID than unvaccinated individuals.

Also Read: Novo Nordisk To Roll Out Obesity Pill Soon? Here’s All You Should Know

AI in COVID Testing

As SARS-CoV-2 evolves through mutations, keeping vaccines effective is a moving target. Come forward EVE-Vax, a sophisticated AI system that computer-generates viral proteins that may be able to bypass immune defenses.

Unlike other approaches that respond to current variants, EVE-Vax anticipates ahead of time how the virus could change. By modeling possible future mutations, this technology could transform the way vaccines and treatments are designed — not only for COVID but for other fast-changing viruses such as influenza and HIV.

Is COVID in 2025 Different?

Though the immediate global crisis is over, COVID-19 in 2025 is an evolving public health concern. While the majority of cases are mild, the virus still presents severe threats to at-risk populations, and long-term complications are increasingly understood.

Public health measures now need to walk a tightrope between caution and flexibility — incorporating technological innovation such as AI modeling and continuing global vaccination programs to pre-empt future surges. The virus has evolved, our response must also evolve.

Recent legal developments have highlighted the importance of advance planning for end-of-life care.

A Living Will is something every adult should consider discussing and creating at some point.

Conversations within families about individual preferences in the event of a terminal illness are an important first step, and these discussions should take place while everyone is still in good health.

Individuals may have very different views about how they wish to be treated if they develop a terminal illness or certain severe, irreversible conditions. For instance, some may not want ventilator support, while others may choose to avoid ICU care.

Some might accept ICU care but prefer not to undergo CPR. Others may prefer not to receive artificial feeding through tubes. Yet others may wish for every possible treatment to be attempted. A few may prefer to spend their final days at home.

Creating A Living Will

It should be noted that a Living Will does not impose any limitation on treatment for common medical conditions such as infections, surgery for curable illnesses, or routine hospital care.

These preferences apply only to situations such as terminal illness—for example, advanced cancer—or irreversible conditions such as a persistent vegetative state.

Creating a Living Will is now relatively straightforward. It must be signed in the presence of two witnesses and attested by a notary or a gazetted officer.

The earlier requirement of countersignature by a Judicial Magistrate has been removed to make the process easier. Templates are also available online that individuals can use as a basis for drafting their own. Before preparing one, it is helpful to discuss the pros and cons of their choices with the family doctor.

It is important to again emphasize that a Living Will is NOT about refusing all treatment, hospitalization, or ICU admission for routine medical care. Rather, it addresses only specific situations.

When such preferences are clearly documented in advance, important decisions about withholding or withdrawing treatment in select circumstances become less contentious.

Doctors and hospitals will no longer be hesitant to withhold unnecessary treatment measures in such situations, as it will already be documented in the patient’s own Living Will. Relatives also will not face the difficult decision of withholding or withdrawing futile medical treatment on behalf of their loved one.

Essentially, the Living Will protects the patient’s wishes when they are no longer able to speak for themselves.

What Happens Without A Living Will

In a terminally ill patient who is unable to communicate, the absence of a Living Will often leads to differences of opinion among family members about what the patient might have wanted.

This uncertainty frequently results in a collective decision to “do everything possible,” just to be on the safe side.

Doctors are reluctant to override the wishes of relatives, even when they believe that further treatment measures are unlikely to be beneficial.

As a result, the patient may receive prolonged medical interventions that neither improve the underlying condition nor enhance quality of life. Once started, these treatments may continue indefinitely until the patient dies naturally.

This may take months, years, or even decades, and also incur huge costs. In the absence of a Living Will, complex legal procedures are required to withdraw these treatments — even if all the relatives are convinced that they should be withdrawn.

Bolivia has reported an outbreak of mosquito-borne Chikungunya virus disease, with cases rising to more than 5,000 nationwide.

Chikungunya is transmitted by the Aedes aegypti and Aedes albopictus mosquitoes -- the same species that spread dengue fever and Zika virus disease. As a result, the disease becomes challenging to diagnose.

The South American country's Ministry of Health, in a statement, shared that "5,371 cases of chikungunya have been registered nationwide".

The worst areas in Bolivia include

• Santa Cruz (4,500 cases)
• Cochabamba (303 cases)
• Tarija (332 cases)
• Chuquisaca (81 cases)
• La Paz (68 cases)

The Ministry informed, "joint efforts to control and manage the vector".

It further noted that an investigation is being conducted to share the results and cause of death, as well as ongoing epidemiological surveillance for all vector-borne disease.

To curb the cases, the Health Ministry noted that "it is supporting the provision of biolarvicide and insecticide for departmental and municipal actions to prevent an increase in cases".

This includes the distribution of about 1,300 liters of insecticide and biological larvicides applied with backpack sprayers, Outbreak News Today reported.

The government also urged the general public to clean weeds from yards and gardens to eliminate the vector’s resting places

Global Cases

In January, the surveillance data from the European Centre for Disease Prevention and Control (ECDC) reported 2,881 cases of Chikungunya virus disease and no associated deaths from 11 countries in European Union this year.

The ECDC noted that the Americas have reported 2,879 cases and one associated death, with Brazil reporting the highest number of cases in 2026.

In addition to Bolivia, other countries in South America reporting chikungunya include Costa Rica, El Salvador, Honduras, and Mexico.

French health authorities also reported a significant rise in chikungunya disease in Mayotte, an overseas department in the Indian Ocean. Since the beginning of 2026, more than 270 confirmed cases have been recorded, Vax-Before-Travel reported.

ECDC data shows that the weekly average of cases in the last two weeks of February 2026 was around 65.

Symptoms And Prevention

There is currently no antiviral drug treatment for chikungunya. While two vaccines against chikungunya have received regulatory approval, it still lacks widespread rollout.

Common symptoms of chikungunya include:

• abrupt onset of fever
• joint and muscle pain
• headache
• nausea
• fatigue
• rash

While serious complications are rare, the elderly and children under one year old may be at risk of long-term symptoms and even death.

The ECDC advised people "to take enhanced measures to prevent mosquito bites".

India's drug regulator, the Central Drugs Standard Control Organization (CDSCO), has threatened pharmaceutical firms with action for promoting GLP-1 weight-loss drugs among the general public.

Glucagon-Like Peptide-1 (GLP-1) receptor agonists are a class of medicines that help lower blood sugar, support weight loss, reduce the risk of heart and kidney complications, and can even lower the risk of early death in people with type 2 diabetes.

In an official circular, the CDSCO warned drug makers from indulging in "direct or indirect advertising" for obesity and metabolic disorders.

The regulatory body also cautioned pharma companies against campaigns using influencers, noting that any violation "could attract regulatory action".

Advertisements, which "function as a surrogate advertisement for prescription-only drugs, shall be viewed seriously and may be treated as irrational or misleading marketing practice", read the letter signed by the Drug Controller General of India (DCGI) Rajeev Raghuvanshi.

The order comes as the CDSCO noted that drugmakers have been engaging in surrogate promotional activities, under the garb of disease awareness campaigns, and digital media outreach.

What The CDSCO Mandated

• Weight-loss drugs, specifically GLP-1 medications, must only be sold with a prescription from a registered medical practitioner.

• There should be no ads, whether direct or indirect, in print, electronic, digital, social media, or any other public platform intended, directly or indirectly, to promote the product to the general public.

• No GLP-1 drugs must exaggerate for therapeutic efficacy; suggest for assured or guaranteed weight loss outcome; and induce demand for pharmacological therapy

• awareness campaigns
• influencer engagement
• corporate campaigns

Rush For Generic Weight Loss Drugs

The government's advisory comes patent for semaglutide -- an active ingredient in diabetes and anti-obesity drugs, specifically Wegovy and Ozempic -- expires on March 20.

This will allow Indian pharma companies to launch cheaper generic versions, significantly increasing affordability and access for millions battling Type 2 diabetes and obesity.

Major Indian drugmakers gearing up to launch their generic semglutide injection in the country in March include Sun Pharmaceutical Industries, Zydus Lifesciences, Alkem Laboratories, Dr. Reddy’s Laboratories, Torrent Pharmaceuticals, and MSN Laboratories.

Obesity A Chronic Metabolic Condition

The CDSCO stressed the importance of "lifestyle modification measures (diet, exercise, behavioural interventions)" in treating obesity.

"Obesity is a chronic metabolic condition requiring comprehensive management, including lifestyle interventions," the regulator said.

"Pharmaceutical therapy, where indicated, must not be projected in a manner that undermines public health initiatives promoting diet control, physical activity, and preventive healthcare," it added.

WHO Guidelines On GLP-1 drugs

Amid increasing prevalence of GLP-1 drugs, the World Health Organisation (WHO), late last year, acknowledged its role in treating obesity.

However, it warned that medications like GLP-1 alone will not solve the problem affecting more than one billion people worldwide.

The global health body also issued conditional recommendations for using these therapies as part of a comprehensive approach that includes healthy diets, regular physical activity, and support from health professionals.